



PROSTATE SPECIFIC ANTIGEN (PSA)- Test Code 6112



Turnaround Time : 2 business days



Specimen Type: 1x SST
Serum

Description

Protein tumour markers are often produced in response to cancer. These markers are essential tools for oncologists in cancer detection, diagnosis, monitoring treatment efficacy and assessing the potential for recurrence (Garg et al., 2023).

Prostate Specific Antigen (PSA) is a protein produced by the prostate gland, with elevated levels often associated with prostate cancer (Garg et al., 2023). PSA is primarily used for prostate cancer screening, monitoring treatment response and detecting recurrence (Garg et al., 2023). However, PSA levels can also be raised in benign prostate conditions, such as prostatitis or benign prostatic hyperplasia (BPH).

In addition to aiding in early detection, protein markers are crucial for monitoring cancer progression and treatment response. A significant drop in marker levels often suggests successful treatment, while rising levels may indicate recurrence or progression (Garg et al., 2023). While tumour markers are valuable in guiding cancer care, they are not definitive and must be interpreted alongside other diagnostic tests, including imaging and biopsies (Garg et al., 2023).

Whats included?

- Prostate Specific Antigen (PSA) – Prostate

Conditions and Symptoms

- Difficulty urinating
- Frequent urination, especially at night (nocturia)
- Pain or burning during urination
- Blood in urine or semen
- Pain in the lower back, hips, or pelvis
- Erectile dysfunction
- Painful ejaculation
- Unexplained weight loss and fatigue

Complementary Testing

- RGCC Onconomics Plus (Test code 7003)

Accreditations Include:

- NATA ISO 15189 – Requirements for Quality and Competence in Medical Laboratories*
- CLIA – Clinical Laboratories Improvement Amendments*



info@nutripath.com.au



1300 688 522



www.nutripath.com.au

For more information
scan the QR code



*See NATA and CLIA website for further details